(Q37978670)

26 August 2017

Evidence-based review of therapeutic plasma exchange in neurological disorders (English)

1 reference

26 August 2017

Vishesh Chhibber

1

1 reference

PubMed ID

22277020

26 August 2017

Robert Weinstein

series ordinal

2

1 reference

26 August 2017

25 January 2012

1 reference

26 August 2017

1 reference

26 August 2017

25

1 reference

26 August 2017

2

1 reference

26 August 2017

132-139

1 reference

Guidelines on the use of therapeutic apheresis in clinical practice--evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis

26 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-139X.2011.01023.X

Evidence-based guideline update: Plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-139X.2011.01023.X

Therapeutic apheresis in neurology critical care

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-139X.2011.01023.X

Therapeutic apheresis in neurological disorders: a survey of the evidence in support of current category I and II indications for therapeutic plasma exchange

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-139X.2011.01023.X

Plasma exchange in neuroimmunological disorders: Part 1: Rationale and treatment of inflammatory central nervous system disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-139X.2011.01023.X

ADEM: distinct disease or part of the MS spectrum?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-139X.2011.01023.X

Acute disseminated encephalomyelitis, multiphasic disseminated encephalomyelitis and multiple sclerosis in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-139X.2011.01023.X

Role of plasmapheresis in acute disseminated (postinfectious) encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-139X.2011.01023.X

The Guillain-Barré syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-139X.2011.01023.X

Anti-peripheral myelin antibody in patients with demyelinating neuropathy: quantitative and kinetic determination of serum antibody by complement component 1 fixation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-139X.2011.01023.X

A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-139X.2011.01023.X

Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-139X.2011.01023.X

Management of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-139X.2011.01023.X

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-139X.2011.01023.X

A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-139X.2011.01023.X

New treatment approaches to myasthenia gravis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-139X.2011.01023.X

Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-139X.2011.01023.X

Plasmapheresis in refractory generalized myasthenia gravis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-139X.2011.01023.X

Comparative effects of plasma exchange and pyridostigmine on respiratory muscle strength and breathing pattern in patients with myasthenia gravis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-139X.2011.01023.X

Practice parameters and focusing research: plasma exchange for myasthenia gravis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-139X.2011.01023.X

Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-139X.2011.01023.X

Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-139X.2011.01023.X

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-139X.2011.01023.X

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-139X.2011.01023.X

Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-139X.2011.01023.X

Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: possible interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-139X.2011.01023.X

Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-139X.2011.01023.X

Successful management of natalizumab-associated progressive multifocal leukoencephalopathy and immune reconstitution syndrome in a patient with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-139X.2011.01023.X

Treatment of progressive multifocal leukoencephalopathy associated with natalizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-139X.2011.01023.X

The clinical course of neuromyelitis optica (Devic's syndrome).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-139X.2011.01023.X

Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-139X.2011.01023.X

Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-139X.2011.01023.X

Neuromyelitis optica: a distinct demyelinating disease of the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-139X.2011.01023.X

Neuromyelitis optica in childhood: case report with sequential MRI findings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-139X.2011.01023.X

Neuromyelitis optica in France: a multicenter study of 125 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-139X.2011.01023.X

Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-139X.2011.01023.X

Multiple sclerosis in the Japanese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-139X.2011.01023.X

Optic neuromyelitis syndrome in Brazilian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-139X.2011.01023.X

A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-139X.2011.01023.X

IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-139X.2011.01023.X

Neuromyelitis optica positive antibodies confer a worse course in relapsing-neuromyelitis optica in Cuba and French West Indies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-139X.2011.01023.X

A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-139X.2011.01023.X

Neuromyelitis optica: concepts in evolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-139X.2011.01023.X

Revised diagnostic criteria for neuromyelitis optica

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-139X.2011.01023.X

The spectrum of neuromyelitis optica

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-139X.2011.01023.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-139X.2011.01023.X

Pure optic-spinal form of multiple sclerosis in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-139X.2011.01023.X

Neuromyelitis optica: current concepts and prospects for future management

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-139X.2011.01023.X

Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-139X.2011.01023.X

Sustained improvement of a girl affected with Devic's disease over 2 years of mycophenolate mofetil treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-139X.2011.01023.X

Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-139X.2011.01023.X

Antibody to aquaporin-4 in the long-term course of neuromyelitis optica

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-139X.2011.01023.X

Immunosuppressive therapy is more effective than interferon in neuromyelitis optica.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-139X.2011.01023.X

Frequency and clinical correlates of anti-neural IgM antibodies in neuropathy associated with IgM monoclonal gammopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-139X.2011.01023.X

The pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection (PANDAS) subgroup: separating fact from fiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-139X.2011.01023.X

Therapeutic plasma exchange and intravenous immunoglobulin for obsessive-compulsive disorder and tic disorders in childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-139X.2011.01023.X

Case study: acute basal ganglia enlargement and obsessive-compulsive symptoms in an adolescent boy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-139X.2011.01023.X

PANDAS with catatonia: a case report. Therapeutic response to lorazepam and plasmapheresis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-139X.2011.01023.X

Pediatric autoimmune neuropsychiatric disorders associated with streptococcus: comparison of diagnosis and treatment in the community and at a specialty clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-139X.2011.01023.X

Chorea in fifty consecutive patients with rheumatic fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-139X.2011.01023.X

Treatment of Sydenham's chorea with intravenous immunoglobulin, plasma exchange, or prednisone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-139X.2011.01023.X

10.1111/J.1525-139X.2011.01023.X

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference

PubMed ID

22277020